Essi Salokangas

Essi Salokangas

Auto-generated profile, based on publicly available information

Essi Salokangas

Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
JNJaviera Navarrete
Javiera Navarrete
Christine HughesChristine Hughes
Christine Hughes
JKJanice Kung
Janice Kung
ESEssi Salokangas
Essi Salokangas
MTMarliss Taylor
Marliss Taylor
EHElaine Hyshka
Elaine Hyshka
Introduction The disparities and risk trajectories experienced by people who use drugs (PWUD) highlight the critical need for equity-oriented strategies. Pharmacy staff (pharmacists, pharmacy technicians and assistants) make essential contributions to public health, and their role in the response to the drug overdose crisis can be understood as an extension of their public health role. Their involvement in overdose prevention strategies, such as take-home naloxone programmes and prescribed opioid medication management, has been documented. Still, their role in harm reduction services for PWUD has yet to be mapped. This gap has led to challenges when implementing harm reduction services in pharmacy-related settings. This review aims to summarise literature that focuses on the implementation of harm reduction services for PWUD provided by pharmacy staff. Methods and analysis This scoping review will adhere to the Arksey and O’Malley framework for conducting scoping reviews. The electronic databases MEDLINE, Embase, CINAHL, Web of Science Core Collection, SCOPUS and Google Scholar were searched on 4 June 2024, using terms related to pharmacy staff, PWUD and harm reduction services. This review will consider peer-reviewed literature in English, Spanish and French focused on describing or evaluating the implementation of harm reduction services for PWUD by pharmacy staff. Two independent reviewers will screen titles and abstracts and conduct the full-text screening to determine eligibility. Findings will be presented as a narrative summary and supported by tabular and graphical formats. Knowledge partner engagement will guide all steps in this study. Ethics and dissemination Formal ethical approval is not required, as primary human or animal data will not be collected. A manuscript summarising the results will be written and submitted to a peer-reviewed journal for publication. Other outlets for dissemination will include local presentations and conference presentations. Trial registration details Open Science Framework (https://osf.io/vn6ht).

2 March 2026 in BMJ Open
Verified
Journal Article
Open access
PDF file
JNJaviera Navarrete
Javiera Navarrete
EBEmily Berg
Emily Berg
Christine HughesChristine Hughes
Christine Hughes
ESEssi Salokangas
Essi Salokangas
MTMarliss Taylor
Marliss Taylor
EHElaine Hyshka
Elaine Hyshka
Objectives The roles of pharmacy staff have expanded to include public health functions, such as delivering harm reduction services for people who use drugs (PWUD), particularly unregulated substances and non-medical drug use, in response to an ongoing drug overdose crisis. Nonetheless, their involvement across the full spectrum of harm reduction services remains underexplored. This study mapped existing research describing or evaluating the implementation of harm reduction services for PWUD provided by pharmacy staff. Design Scoping review. Data sources MEDLINE, EMBASE, CINAHL, Web of Science, Scopus and Cochrane Library (inception to July 2025). Study selection Studies reporting on the description or evaluation of harm reduction services for PWUD provided by pharmacy staff. Data extraction Two team members screened studies for eligibility and extracted the data. The data were analysed primarily to describe harm reduction services and the role of pharmacy staff. Results 43 articles were included. The most frequently reported harm reduction services were sexually transmitted and blood-borne infection care (33%), needle and syringe programmes (21%), naloxone distribution (19%) and medication treatment for opioid use disorder (19%). Pharmacy staff were integrated into multidisciplinary teams (79%), with their roles varying from education to medication prescribing. Included studies reported harm reduction services for PWUD delivered by pharmacy staff as effective, feasible and safe. However, implementations were not tailored to equity-deserving populations. Services primarily addressed opioid-related harms, while strategies focusing on the use of non-opioid substances were limited. Conclusion This scoping review highlights the diverse roles pharmacy staff play in delivering harm reduction services for PWUD. Positioned at the intersection of accessibility and healthcare delivery, pharmacy staff are ideally situated to expand access to equitable care. To fully harness this potential, future research and practice should embed harm reduction as a core philosophy, extending beyond individual interventions to support the creation of person-centred, non-judgmental and low-barrier services.